Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Agenus Inc.
< Previous
1
2
Next >
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
October 26, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
October 10, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus To Host BOT/BAL Program Update at ESMO 2023
October 05, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus to Participate in September Investor Conferences
August 28, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
August 23, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Second Quarter 2023 Results
August 08, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
July 28, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Expands Executive Leadership Team
July 20, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
June 05, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
May 09, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
April 17, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
March 30, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
INKT
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
March 27, 2023
From
Agenus Inc.
Via
Business Wire
Tickers
AGEN
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
March 14, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
March 12, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
March 11, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
February 28, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
February 28, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Participate in February Investor Conferences
January 26, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
January 23, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
January 10, 2023
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
December 21, 2022
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
November 17, 2022
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
November 16, 2022
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
November 14, 2022
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
November 08, 2022
From
Agenus Inc.
Via
GlobeNewswire
Tickers
AGEN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.